key: cord-0900344-9w250axp
authors: Levy, Jerrold H.; Mamoun, Negmeldeen; Shaz, Beth
title: Commentary: Patient blood management in COVID19- is anything really different?
date: 2021-01-13
journal: JTCVS open
DOI: 10.1016/j.xjon.2021.01.004
sha: d1b3fc2dac45c695d58191bf7ddc5391b7fb219d
doc_id: 900344
cord_uid: 9w250axp

nan

Multiple strategies for patient blood management (PBM) are published for clinicians to guide blood transfusion reduction and improve appropriate blood use. 1 In the current COVID-19 pandemic, the critical question is what's different beyond the critical illness and coagulopathy? 2 Donor blood availability with current restrictions, lack of workplace attendance, and potential concerns of viral exposure to donors has restricted our donor pool, but reducing allogeneic blood use has always been important for improving patient outcomes, reducing costs, and avoiding transfusion-associated adverse events. However, most strategies directed at PBM are simply anemia management and exclude other essential transfused products: platelets, plasma, and cryoprecipitate. Given the frequent platelet shortages that are critical in the setting of cardiac surgery, PBM needs to be expanded beyond anemia management, the focus of Perelman's article. 3 Now is the time to stop having red blood cells (RBCs) the sole focus of PBM strategies. Other blood products, including plasma, cryoprecipitate, and platelets, have shortages, cause adverse events, and are used inappropriately. Examples of expanding PBM include using fibrinogen concentrate instead of cryoprecipitate to replete fibrinogen. 4 Other factor concentrates can be used, including prothrombin complex concentrates for bleeding 5 and antithrombin for heparin resistance instead of plasma. 6 Regarding platelets, which are extensively used in cardiac surgery, better clinical studies and guidelines are needed, as there is no high-quality evidence beyond guidance/guideline documents to support their administration in bleeding patients. 7 In summary, it's time to stop focusing on anemia and red blood cell administration and expand our efforts to reduce all blood product use by performing studies to determine appropriate clinical use and expanding the use and development of potential substitutes. There are multiple areas to improve PBM. We need to improve RBC transfusion triggers beyond specific hemoglobin levels and instead focus on examination of physiologic endpoints for administration.

We also have factor concentrates available that can be increasingly used for surgical bleeding.

For platelet transfusions, the potential for cold-stored platelets provides other potential mechanisms to increase the availability of platelets when needed. 10 

Concepts of blood transfusion in adults

COVID-19 and its implications for thrombosis and anticoagulation

Preoperative anemia management in the COVID era

How I use fibrinogen replacement therapy in acquired bleeding

Prothrombin complex concentrates in trauma and perioperative bleeding

Antithrombin: anti-inflammatory properties and clinical applications

What is the evidence for platelet transfusion in perioperative settings?

Platelet transfusion: a systematic review of the clinical evidence

proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium

Warming Up to Cold-stored Platelets